PD16-01 SYNERGISTIC EFFECTS OF CURCUMIN AND LACTOFERRIN TO INHIBIT THE PROSTATIC CANCER CELLS GROWTH AND MIGRATION ABILITY

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD16-01 SYNERGISTIC EFFECTS OF CURCUMIN AND LACTOFERRIN TO INHIBIT THE PROSTATIC CANCER CELLS GROWTH AND MIGRATION ABILITY Erica Costantini, Michele Marchioni, Lisa Aielli, Simone Ferretti, Antonio De Palma, Davide Ciavarella, Giulio Litterio, Marcella Reale, Marta Di Nicola, and Luigi Schips Erica CostantiniErica Costantini More articles by this author , Michele MarchioniMichele Marchioni More articles by this author , Lisa AielliLisa Aielli More articles by this author , Simone FerrettiSimone Ferretti More articles by this author , Antonio De PalmaAntonio De Palma More articles by this author , Davide CiavarellaDavide Ciavarella More articles by this author , Giulio LitterioGiulio Litterio More articles by this author , Marcella RealeMarcella Reale More articles by this author , Marta Di NicolaMarta Di Nicola More articles by this author , and Luigi SchipsLuigi Schips More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003271.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Castration resistant prostate cancer (CRPC) represents a challenge in urologic oncology. Several treatments are available for this tumor, but their efficacy tends to reduce in time. In recent years, several natural compounds have been tested as possible adjuvant treatment in CRPC patients. Among the other curcumin (CU) showed interesting bioactive properties, but low penetration within cells. We hypothesized that the combination with lactoferrin (LF) might exert a synergistic effect on prostatic cancer cells as anti-cancer. Their effects have been evaluated in PC3 and DU145 prostate cancer cells, that are in vitro models of CRPC. METHODS: Human CRPC cell lines (DU-145, PC3) were cultured in medium added with or without LF (175 µM) ± CU (2.5 µg/ml and 5 µg/ml). Cell viability was determined using a standard colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) reduction assay. To test ability of cell migration observation at 6 and 24 h after scratch wounds were made. Quantitative Real-time PCR was performed to evaluate gene expression of death receptors (DR) and integrins (α3/β1). The human annexin V ELISA assay was used for the quantitative detection of annexin V, involved in apoptosis regulation. RESULTS: In PC3 cells, the proliferation rate is reduced by treatments alone or in association, with a significant reduction in presence of CU, both at 2.5 (p=0.007) and 5 ug/ml (p=0.001), in a dose-dependent manner. In DU145 cells, the inhibitory effect of CU is more significant in presence of LF. In PC3 migration, LF significantly weakened invasion capacity with an increase of the cell-free area of 24.9%, 31.8%, and 24% respectively in presence of LF alone, CU2.5+LF and CU5+LF, after 6 h, with similar results in DU145 cells. In accord the integrins α3/β1, showed a significant reduction in both prostate cell lines, in presence of CU2.5, CU5, and LF175 and their combination (p<0.005). Moreover, in PC3 and DU145 an upregulation of pro-apoptotic DR4 and DR5 gene expression have been observed. Finally, in both PC3 and DU145 cells line an increased concentration of human annexin V, a marker of apoptosis, have been recorded (p<0.005). CONCLUSIONS: Our results showed that the association of CU and LF might led to beneficial effect on CRPC prostate cancer reducing the proliferative activity of cancerous cells and their ability to migrate and produce metastases. In addition, we can suggest a potential pro-apoptotic effect of CU and LF leading to a potential application as an adjuvant treatment for the treatment of CRPC. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e489 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Erica Costantini More articles by this author Michele Marchioni More articles by this author Lisa Aielli More articles by this author Simone Ferretti More articles by this author Antonio De Palma More articles by this author Davide Ciavarella More articles by this author Giulio Litterio More articles by this author Marcella Reale More articles by this author Marta Di Nicola More articles by this author Luigi Schips More articles by this author Expand All Advertisement PDF downloadLoading ...